Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study
Identifieur interne : 001C33 ( Istex/Corpus ); précédent : 001C32; suivant : 001C34Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study
Auteurs : Pierre Payoux ; Kader Boulanouar ; Christine Sarramon ; Nelly Fabre ; Sylvie Descombes ; Monique Galitsky ; Claire Thalamas ; Christine Brefel-Courbon ; Umberto Sabatini ; Claude Manelfe ; François Chollet ; Laurent Schmitt ; Olivier RascolSource :
- Movement Disorders [ 0885-3185 ] ; 2004-01.
English descriptors
- KwdEn :
Abstract
Akinesia is associated with supplementary motor area (SMA) dysfunction in Parkinson's disease. We looked for a similar association in patients with schizophrenia. Using functional magnetic resonance imaging (fMRI), we compared motor activation in 6 akinetic neuroleptic‐treated schizophrenic patients and 6 normal subjects. Schizophrenic patients had a defective activation in the SMA, left primary sensorimotor cortex, bilateral lateral premotor and inferior parietal cortices, whereas the right primary sensorimotor cortex and a mesial frontal area were hyperactive. SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia‐related abnormal intracortical connections. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10598
Links to Exploration step
ISTEX:CFBE2A0D97A32DF721673F789F525393693D3DC4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Boulanouar, Kader" sort="Boulanouar, Kader" uniqKey="Boulanouar K" first="Kader" last="Boulanouar">Kader Boulanouar</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sarramon, Christine" sort="Sarramon, Christine" uniqKey="Sarramon C" first="Christine" last="Sarramon">Christine Sarramon</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Descombes, Sylvie" sort="Descombes, Sylvie" uniqKey="Descombes S" first="Sylvie" last="Descombes">Sylvie Descombes</name><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Galitsky, Monique" sort="Galitsky, Monique" uniqKey="Galitsky M" first="Monique" last="Galitsky">Monique Galitsky</name><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name><affiliation><mods:affiliation>Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Manelfe, Claude" sort="Manelfe, Claude" uniqKey="Manelfe C" first="Claude" last="Manelfe">Claude Manelfe</name><affiliation><mods:affiliation>Department of Neuroradiology, University Hospital of Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Chollet, Francois" sort="Chollet, Francois" uniqKey="Chollet F" first="François" last="Chollet">François Chollet</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schmitt, Laurent" sort="Schmitt, Laurent" uniqKey="Schmitt L" first="Laurent" last="Schmitt">Laurent Schmitt</name><affiliation><mods:affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CFBE2A0D97A32DF721673F789F525393693D3DC4</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.10598</idno><idno type="url">https://api.istex.fr/document/CFBE2A0D97A32DF721673F789F525393693D3DC4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Boulanouar, Kader" sort="Boulanouar, Kader" uniqKey="Boulanouar K" first="Kader" last="Boulanouar">Kader Boulanouar</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sarramon, Christine" sort="Sarramon, Christine" uniqKey="Sarramon C" first="Christine" last="Sarramon">Christine Sarramon</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Descombes, Sylvie" sort="Descombes, Sylvie" uniqKey="Descombes S" first="Sylvie" last="Descombes">Sylvie Descombes</name><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Galitsky, Monique" sort="Galitsky, Monique" uniqKey="Galitsky M" first="Monique" last="Galitsky">Monique Galitsky</name><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sabatini, Umberto" sort="Sabatini, Umberto" uniqKey="Sabatini U" first="Umberto" last="Sabatini">Umberto Sabatini</name><affiliation><mods:affiliation>Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Manelfe, Claude" sort="Manelfe, Claude" uniqKey="Manelfe C" first="Claude" last="Manelfe">Claude Manelfe</name><affiliation><mods:affiliation>Department of Neuroradiology, University Hospital of Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Chollet, Francois" sort="Chollet, Francois" uniqKey="Chollet F" first="François" last="Chollet">François Chollet</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schmitt, Laurent" sort="Schmitt, Laurent" uniqKey="Schmitt L" first="Laurent" last="Schmitt">Laurent Schmitt</name><affiliation><mods:affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>INSERM U 455, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-01">2004-01</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="83">83</biblScope><biblScope unit="page" to="90">90</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CFBE2A0D97A32DF721673F789F525393693D3DC4</idno><idno type="DOI">10.1002/mds.10598</idno><idno type="ArticleID">MDS10598</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>akinesia</term><term>fMRI</term><term>neuroleptics</term><term>schizophrenia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Akinesia is associated with supplementary motor area (SMA) dysfunction in Parkinson's disease. We looked for a similar association in patients with schizophrenia. Using functional magnetic resonance imaging (fMRI), we compared motor activation in 6 akinetic neuroleptic‐treated schizophrenic patients and 6 normal subjects. Schizophrenic patients had a defective activation in the SMA, left primary sensorimotor cortex, bilateral lateral premotor and inferior parietal cortices, whereas the right primary sensorimotor cortex and a mesial frontal area were hyperactive. SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia‐related abnormal intracortical connections. © 2003 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Pierre Payoux MD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string><json:string>PET Center, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Kader Boulanouar MD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string></affiliations></json:item><json:item><name>Christine Sarramon MD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string><json:string>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Nelly Fabre MD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string><json:string>Department of Neurology, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Sylvie Descombes MD</name><affiliations><json:string>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Monique Galitsky MD</name><affiliations><json:string>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Claire Thalamas MD</name><affiliations><json:string>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Christine Brefel‐Courbon MD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string><json:string>Department of Clinical Pharmacology, University Hospital of Toulouse, France</json:string></affiliations></json:item><json:item><name>Umberto Sabatini MD, PhD</name><affiliations><json:string>Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Roma, Italy</json:string></affiliations></json:item><json:item><name>Claude Manelfe MD, PhD</name><affiliations><json:string>Department of Neuroradiology, University Hospital of Toulouse, France</json:string></affiliations></json:item><json:item><name>François Chollet MD, PhD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string><json:string>PET Center, University Hospital of Toulouse, Toulouse, France</json:string><json:string>Department of Neurology, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Laurent Schmitt MD, PhD</name><affiliations><json:string>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>INSERM U 455, Toulouse, France</json:string><json:string>PET Center, University Hospital of Toulouse, Toulouse, France</json:string><json:string>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</json:string><json:string>Department of Clinical Pharmacology, University Hospital of Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>schizophrenia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>akinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>fMRI</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroleptics</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Akinesia is associated with supplementary motor area (SMA) dysfunction in Parkinson's disease. We looked for a similar association in patients with schizophrenia. Using functional magnetic resonance imaging (fMRI), we compared motor activation in 6 akinetic neuroleptic‐treated schizophrenic patients and 6 normal subjects. Schizophrenic patients had a defective activation in the SMA, left primary sensorimotor cortex, bilateral lateral premotor and inferior parietal cortices, whereas the right primary sensorimotor cortex and a mesial frontal area were hyperactive. SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia‐related abnormal intracortical connections. © 2003 Movement Disorder Society</abstract><qualityIndicators><score>5.614</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>805</abstractCharCount><pdfWordCount>4354</pdfWordCount><pdfCharCount>29512</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>105</abstractWordCount></qualityIndicators><title>Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>7</total><last>90</last><first>83</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.10598</json:string></doi><id>CFBE2A0D97A32DF721673F789F525393693D3DC4</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/CFBE2A0D97A32DF721673F789F525393693D3DC4/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/CFBE2A0D97A32DF721673F789F525393693D3DC4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/CFBE2A0D97A32DF721673F789F525393693D3DC4/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><notesStmt><note>Institut National de la Santé et de la Recherche Médicale</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title><author><persName><forename type="first">Pierre</forename><surname>Payoux</surname><roleName type="degree">MD</roleName></persName><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Kader</forename><surname>Boulanouar</surname><roleName type="degree">MD</roleName></persName><affiliation>INSERM U 455, Toulouse, France</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Sarramon</surname><roleName type="degree">MD</roleName></persName><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Nelly</forename><surname>Fabre</surname><roleName type="degree">MD</roleName></persName><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Sylvie</forename><surname>Descombes</surname><roleName type="degree">MD</roleName></persName><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Monique</forename><surname>Galitsky</surname><roleName type="degree">MD</roleName></persName><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Claire</forename><surname>Thalamas</surname><roleName type="degree">MD</roleName></persName><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Brefel‐Courbon</surname><roleName type="degree">MD</roleName></persName><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</affiliation></author><author><persName><forename type="first">Umberto</forename><surname>Sabatini</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Roma, Italy</affiliation></author><author><persName><forename type="first">Claude</forename><surname>Manelfe</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neuroradiology, University Hospital of Toulouse, France</affiliation></author><author><persName><forename type="first">François</forename><surname>Chollet</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</affiliation><affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Laurent</forename><surname>Schmitt</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</p></note><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</affiliation><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation><affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-01"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="83">83</biblScope><biblScope unit="page" to="90">90</biblScope></imprint></monogr><idno type="istex">CFBE2A0D97A32DF721673F789F525393693D3DC4</idno><idno type="DOI">10.1002/mds.10598</idno><idno type="ArticleID">MDS10598</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Akinesia is associated with supplementary motor area (SMA) dysfunction in Parkinson's disease. We looked for a similar association in patients with schizophrenia. Using functional magnetic resonance imaging (fMRI), we compared motor activation in 6 akinetic neuroleptic‐treated schizophrenic patients and 6 normal subjects. Schizophrenic patients had a defective activation in the SMA, left primary sensorimotor cortex, bilateral lateral premotor and inferior parietal cortices, whereas the right primary sensorimotor cortex and a mesial frontal area were hyperactive. SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia‐related abnormal intracortical connections. © 2003 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>schizophrenia</term></item><item><term>akinesia</term></item><item><term>fMRI</term></item><item><term>neuroleptics</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2002-12-20">Received</change><change when="2003-07-04">Registration</change><change when="2004-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/CFBE2A0D97A32DF721673F789F525393693D3DC4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v19:1</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2004-01">January 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="140" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10598</doi><idGroup><id type="unit" value="MDS10598"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2003 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2002-12-20"></event><event type="manuscriptRevised" date="2003-04-22"></event><event type="manuscriptAccepted" date="2003-07-04"></event><event type="firstOnline" date="2003-09-29"></event><event type="publishedOnlineFinalForm" date="2004-01-06"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2003-09-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">83</numbering><numbering type="pageLast">90</numbering></numberingGroup><correspondenceTo>Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10598.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="32"></count><count type="wordTotal" number="4388"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title><title type="short" xml:lang="en">Motor Activation in Akinetic Schizophrenia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Pierre</givenNames><familyName>Payoux</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kader</givenNames><familyName>Boulanouar</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Christine</givenNames><familyName>Sarramon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af4"><personName><givenNames>Nelly</givenNames><familyName>Fabre</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Sylvie</givenNames><familyName>Descombes</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Monique</givenNames><familyName>Galitsky</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Claire</givenNames><familyName>Thalamas</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1 #af6"><personName><givenNames>Christine</givenNames><familyName>Brefel‐Courbon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Umberto</givenNames><familyName>Sabatini</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Claude</givenNames><familyName>Manelfe</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1 #af2 #af4"><personName><givenNames>François</givenNames><familyName>Chollet</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Laurent</givenNames><familyName>Schmitt</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af1 #af2 #af5 #af6" corresponding="yes"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>rascol@cict.fr</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U 455, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>PET Center, University Hospital of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="FR" type="organization"><unparsedAffiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="IT" type="organization"><unparsedAffiliation>Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Roma, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neuroradiology, University Hospital of Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">schizophrenia</keyword><keyword xml:id="kwd2">akinesia</keyword><keyword xml:id="kwd3">fMRI</keyword><keyword xml:id="kwd4">neuroleptics</keyword></keywordGroup><fundingInfo><fundingAgency>Institut National de la Santé et de la Recherche Médicale</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Akinesia is associated with supplementary motor area (SMA) dysfunction in Parkinson's disease. We looked for a similar association in patients with schizophrenia. Using functional magnetic resonance imaging (fMRI), we compared motor activation in 6 akinetic neuroleptic‐treated schizophrenic patients and 6 normal subjects. Schizophrenic patients had a defective activation in the SMA, left primary sensorimotor cortex, bilateral lateral premotor and inferior parietal cortices, whereas the right primary sensorimotor cortex and a mesial frontal area were hyperactive. SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia‐related abnormal intracortical connections. © 2003 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Motor Activation in Akinetic Schizophrenia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study</title></titleInfo><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Payoux</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kader</namePart><namePart type="family">Boulanouar</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Sarramon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nelly</namePart><namePart type="family">Fabre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sylvie</namePart><namePart type="family">Descombes</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Monique</namePart><namePart type="family">Galitsky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claire</namePart><namePart type="family">Thalamas</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel‐Courbon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Umberto</namePart><namePart type="family">Sabatini</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione Santa Lucia, Roma, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claude</namePart><namePart type="family">Manelfe</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neuroradiology, University Hospital of Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Chollet</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</affiliation><affiliation>Department of Neurology, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurent</namePart><namePart type="family">Schmitt</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>INSERM U 455, Toulouse, France</affiliation><affiliation>PET Center, University Hospital of Toulouse, Toulouse, France</affiliation><affiliation>Clinical Investigation Centre, University Hospital of Toulouse, Toulouse, France</affiliation><affiliation>Department of Clinical Pharmacology, University Hospital of Toulouse, France</affiliation><description>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées J. Guesde, 31073 Toulouse Cedex, France</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-01</dateIssued><dateCaptured encoding="w3cdtf">2002-12-20</dateCaptured><dateValid encoding="w3cdtf">2003-07-04</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">32</extent><extent unit="words">4388</extent></physicalDescription><abstract lang="en">Akinesia is associated with supplementary motor area (SMA) dysfunction in Parkinson's disease. We looked for a similar association in patients with schizophrenia. Using functional magnetic resonance imaging (fMRI), we compared motor activation in 6 akinetic neuroleptic‐treated schizophrenic patients and 6 normal subjects. Schizophrenic patients had a defective activation in the SMA, left primary sensorimotor cortex, bilateral lateral premotor and inferior parietal cortices, whereas the right primary sensorimotor cortex and a mesial frontal area were hyperactive. SMA was hypoactive in akinetic schizophrenic patients, emphasizing the role of this area in motor slowness. Other abnormal signals likely reflect schizophrenia‐related abnormal intracortical connections. © 2003 Movement Disorder Society</abstract><note type="funding">Institut National de la Santé et de la Recherche Médicale</note><subject lang="en"><genre>Keywords</genre><topic>schizophrenia</topic><topic>akinesia</topic><topic>fMRI</topic><topic>neuroleptics</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>83</start><end>90</end><total>7</total></extent></part></relatedItem><identifier type="istex">CFBE2A0D97A32DF721673F789F525393693D3DC4</identifier><identifier type="DOI">10.1002/mds.10598</identifier><identifier type="ArticleID">MDS10598</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2003 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:CFBE2A0D97A32DF721673F789F525393693D3DC4
|texte= Cortical motor activation in akinetic schizophrenic patients: A pilot functional MRI study
}}
| This area was generated with Dilib version V0.6.23. |  |